MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments
This article was originally published in The Pink Sheet Daily
MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.
You may also be interested in...
Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.